Sarcopenia: burden and challenges for public health.
Beaudart C, Rizzoli R, Bruyère O, Reginster JY, Biver E. · 2014
Read Sarcopenia: burden and challenges for public health. by Beaudart C, Rizzoli R, Bruyère O, Reginster JY, Biver E. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4373245.txt.
Introduction
Charlotte Beaudart, René Rizzoli, Olivier Bruyère, Jean-Yves Reginster, and Emmanuel Biver assessed sarcopenia as a public health problem in Archives of Public Health in 2014. Sarcopenia is the loss of muscle mass and function that comes with aging. It raises falls, disability, and care costs, for patients and for society. Yet experts still lack one agreed definition, which makes its true scale hard to pin down.
The authors review what is known about how common the condition is and what it costs in health and money, at personal and national levels. They stress that an aging world population makes the burden grow fast. Prevention and treatment programs that work broadly are needed, they argue, but building them first requires shared measures. The piece frames muscle loss in old age as a policy issue, not only a medical one.
Catalog record
| CREATOR | Beaudart C, Rizzoli R, Bruyère O, Reginster JY, Biver E. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Sarcopenia: burden and challenges for public health By Charlotte Beaudart, René Rizzoli, Olivier Bruyère, Jean-Yves Reginster, Emmanuel Biver Published in: Archives of Public Health DOI: 10.1186/2049-3258-72-45 ABSTRACT Sarcopenia, operationally defined as the loss of muscle mass and muscle function, is a major health condition associated with ageing, and contributes to many components of public health at both the patient and the societal levels. Currently, no consensual definition of sarcopenia exists and therefore it is still a challenge to establish the actual prevalence of sarcopenia or to establish the direct and indirect impacts of sarcopenia on public health. Anyway, this geriatric syndrome represents a huge potential public health issue because of its multiple clinical and societal consequences. Moreover, all these aspects have an impact on healthcare costs both for the patient and the society. Therefore, the implementation of effective and broadly applicable preventive and therapeutic interventions has become a medical and societal challenge for the growing number of older persons affected by sarcopenia and its disabling complications. Electronic supplementary material The online version of this article (doi:10.1186/2049-3258-72-45) contains supplementary material, which is available to authorized users. BACKGROUND Thanks to social, health and technological progress, the proportion of older people in the age pyramid is increasing all over the world. According to the World Health Organisation, in 2050 there should be at least 2 milliards of people aged 65 years or older, compared to 600 million today. The life expectancy is also increasing and is estimated around 80 years in industrial countries [1]. The aging process is responsible of many changes in body composition including a loss of skeletal muscle mass. From the age of 25, there is a progressive decrease in the size and number of muscle fibres resulting in a loss of about 30% of muscle mass at the age of 80 [2]. Beyond some defined threshold, this age-related loss of muscle mass is characterized as abnormal. To characterize this phenomenon, the term “sarcopenia” was firstly introduced by Irwin Rosenberg [3]. The definition of sarcopenia was then enriched with scientific and technological advances and gradually evolved to incorporate the notions of decreased muscle mass [4], then of decreased muscle function (low muscle strength or low physical performance) [5–11]. These definitions differ from each other in regards to muscle mass indicators (ratio of appendicular lean mass over height squared, ALM/ht2, or over body mass index, ALMBMI), the cutpoints for slow gait speed and whether or not they include a measure of weakness (Table 1). However, there is actually no universal consensus for an operational definition of sarcopenia, which is an important issue for public health.Table 1 Proposed operational definitions of sarcopenia CriteriaMuscle massMuscle functionMuscle strengthPhysical performanceBaumgartner criteria [4]SarcopeniaASM/ ht2 > 2 SD below young healthy meanxxEuropean Society for Clinical Nutrition and Metabolism Special Interest Groups (ESPEN-SIG) [7]SarcopeniaPercentage of muscle mass ≥2 SD below mean in young adults of the same sex and ethnic background (individuals aged 18–39 years in the NHANES III cohort)xGait speed: <0.8 m/s or Reduced performance in any functional test used for comprehensive geriatric assessmentEuropean Working Group on Sarcopenia in Older People (EWGSOP) [8]SarcopeniaALM/ht2 Grip strengthORGait speed: <0.8 m/s- Men: ≤7.23 kg/m2 - Men: <30 kg- Women: ≤5.67 kg/m2 - Women: <20 kgSevere sarcopeniaANDInternational Working Group on Sarcopenia (IWGS) [9]SarcopeniaALM/ht2 xGait speed: <1.0 m/s- Men: ≤7.23 kg/m2 - Women: ≤5.67 kg/m2 Society of Sarcopenia, Cachexia and Wasting Disorders [10]Sarcopenia with limited mobilityALM/ht2 > of 2 SD below the mean of healthy persons aged 20–30 years of the same ethnic groupxGait speed: ≤1.0 m/s or Walking distance < 400 m during a 6-min walkFoundation of NIH Sarcopenia Project [11]Weakness and low lean massALMBMI Grip strengthx- Men: <0.789- Men: <26 kg- Women: <0.512- Women: <16 kgSlowness with weakness and low lean massANDGait speed: ≤0.8 m/sASM/ ht2 = ratio of appendicular skeletal muscle mass over height squared; ALM/ht2 = ratio of appendicular lean mass over height squared; ALMBMI = ratio of appendicular lean mass over body mass index; SD standard deviation. A wide range of techniques can be used to measure the different components of sarcopenia [12]. Three techniques can be used for the measurement of appendicular lean mass: body imaging techniques, bio impedance analysis and anthropometry measures. In research, the two gold standards are the computed tomography (CT-scan) and the magnetic resonance imaging (MRI). However, because of the high costs and the limited access to this kind of equipment, the European Working Group on Sarcopenia in Older People (EWGSOP) [8] recommends in clinical practice, first the use of either dual energy X-ray absorptiometry (DXA) or, as a portable alternative to DXA, the bioelectrical impedance analysis (BIA). Despite their easy use in clinical practice, the anthropometric measures are not recommended for the diagnosis of sarcopenia because these measures are not validated in older people and are, therefore, vulnerable to error. Several techniques are also available for the measurement of muscle strength. Three techniques could potentially be used for the diagnosis of sarcopenia: handgrip strength, knee flexion or knee extension strength and the measurement of peak expiratory flow. In clinical research, the handgrip strength is the most widespread method. Indeed, this method does not require any special equipment, has been documented as a good marker of physical performance among community-dwelling older people and is well correlated with leg strength [13, 14]. Finally, the physical performance can be measured by the “short physical performance battery test (SPPB)”, by the “usual gait speed” or by the “timed up and go test” or “stair climb power test”. The EWGSOP [8] recommends the use of either the usual gait speed, measured on a 4-meter distance or the SPPB test [15] which is a composite measuring walk speed, balance and the ability to stand up 5 times from a chair. Different cut-offs have been developed by the EWGSOP for each variable and could be applied for the diagnosis of sarcopenia. Recently, the Foundation of NIH Sarcopenia Project proposed recommendations for cut-off points for weakness and low lean mass definitions aiming to provide an operational definition for sarcopenia. It was recommended to assess muscle strength by grip strength with cutpoints <26 kg in men and <16 kg in women, and low lean mass by appendicular lean mass adjusted to BMI, with respective cutpoints <0.789 kg/m2 and <0.512 kg/m2[16]. Given the variability in the definitions of sarcopenia, it is still a challenge to establish the actual prevalence of sarcopenia according to age and gender and to assess the direct and indirect impacts of sarcopenia on public health. The aim of this review is to discuss, both broadly and specifically, the public health implication of sarcopenia and its association with objectives health-related outcomes such as falls, fractures, admission in nursing homes or mortality. DISCUSSION Epidemiology of sarcopenia Sarcopenia is very common in older people. Currently it is still a public health challenge to establish a prevalence of sarcopenia. Indeed, this estimated prevalence depends on the type of studied population. A large number of studies have assessed the prevalence of sarcopenia within a cohort of adult subjects and this estimated prevalence could range from 0.1% to 85.4% according to patients’ characteristics [17–22]. Globally, a higher prevalence of sarcopenia is often observed in men, in elderly subjects, in subjects living in nursing